PMID- 24499825
OWN - NLM
STAT- MEDLINE
DCOM- 20160204
LR  - 20220408
IS  - 1435-5922 (Electronic)
IS  - 0944-1174 (Linking)
VI  - 50
IP  - 1
DP  - 2015 Jan
TI  - Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors 
      in Japan: a nationwide survey analysis.
PG  - 58-64
LID - 10.1007/s00535-014-0934-2 [doi]
AB  - BACKGROUND: Although neuroendocrine tumors (NETs) are rare, the number of 
      patients with NET is increasing. However, in Japan, there have been no 
      epidemiological studies on NET since 2005; thus, the prevalence of NET remains 
      unknown. METHODS: We reported the epidemiology of gastroenteropancreatic 
      neuroendocrine tumors (GEP-NETs) [pancreatic neuroendocrine tumors (PNETs) and 
      gastrointestinal neuroendocrine tumors (GI-NETs)] in Japan in 2005. Here, we 
      conducted the second nationwide survey on patients with GEP-NETs who received 
      treatment in 2010. RESULTS: A total of 3,379 patients received treatment for 
      PNETs in 2010, representing a 1.2-fold increase in the number of patients from 
      2005 to 2010. The prevalence was estimated to be 2.69/100,000, with an annual 
      onset incidence of 1.27/100,000 in 2010. Non-functioning tumor (NF)-PNETs 
      comprised 65.5% of cases followed by insulinoma (20.9%) and gastrinoma (8.2%). 
      Interestingly, the number of patients with NF-PNETs increased ~1.8 fold since 
      2005. A total of 19.9% of patients exhibited distant metastasis at initial 
      diagnosis; 4.3% had complications with multiple endocrine neoplasia type 1 
      (MEN-1), and only 4.0% had NF-PNETs associated with MEN-1. Meanwhile, an 
      estimated 8,088 patients received treatment for GI-NETs, representing a ~1.8-fold 
      increase since 2005. The prevalence was estimated to be 6.42/100,000, with an 
      annual onset incidence of 3.51/100,000. The locations of GI-NETs varied: foregut, 
      26.1%; midgut, 3.6%; and hindgut, 70.3%. Distant metastasis and complications 
      with MEN-1 were observed in 6.0 and 0.42% at initial diagnosis, respectively. The 
      frequency of carcinoid syndrome in patients with GI-NETs was 3.2%. CONCLUSION: We 
      clarified the epidemiological changes in GEP-NETs from 2005 to 2010 in Japan.
FAU - Ito, Tetsuhide
AU  - Ito T
AD  - Department of Medicine and Bioregulatory Science, Graduate School of Medical 
      Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, 
      Japan, itopapa@intmed3.med.kyushu-u.ac.jp.
FAU - Igarashi, Hisato
AU  - Igarashi H
FAU - Nakamura, Kazuhiko
AU  - Nakamura K
FAU - Sasano, Hironobu
AU  - Sasano H
FAU - Okusaka, Takuji
AU  - Okusaka T
FAU - Takano, Koji
AU  - Takano K
FAU - Komoto, Izumi
AU  - Komoto I
FAU - Tanaka, Masao
AU  - Tanaka M
FAU - Imamura, Masayuki
AU  - Imamura M
FAU - Jensen, Robert T
AU  - Jensen RT
FAU - Takayanagi, Ryoichi
AU  - Takayanagi R
FAU - Shimatsu, Akira
AU  - Shimatsu A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140206
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
SB  - IM
MH  - Gastrointestinal Neoplasms/*epidemiology/pathology
MH  - Health Surveys
MH  - Humans
MH  - Japan/epidemiology
MH  - Malignant Carcinoid Syndrome/epidemiology
MH  - Multiple Endocrine Neoplasia Type 1/epidemiology
MH  - Neuroendocrine Tumors/*epidemiology/pathology/secondary
MH  - Pancreatic Neoplasms/*epidemiology/pathology
MH  - Prevalence
EDAT- 2014/02/07 06:00
MHDA- 2016/02/05 06:00
CRDT- 2014/02/07 06:00
PHST- 2013/07/29 00:00 [received]
PHST- 2014/01/10 00:00 [accepted]
PHST- 2014/02/07 06:00 [entrez]
PHST- 2014/02/07 06:00 [pubmed]
PHST- 2016/02/05 06:00 [medline]
AID - 10.1007/s00535-014-0934-2 [doi]
PST - ppublish
SO  - J Gastroenterol. 2015 Jan;50(1):58-64. doi: 10.1007/s00535-014-0934-2. Epub 2014 
      Feb 6.